Regarding the FFAR, both GPR41 and GPR43 are closely related to metabolic processes and have become potential targets for the treatment of type 2 diabetes, cardiovascular disease, and metabolic syndrome (19). This evidence concerns the gene FFAR2 and metabolic syndrome.